Estimating relapse time distribution from longitudinal biomarker trajectories using iterative regression and continuous time Markov processes

Alice Cleynen · 2025

Read Estimating relapse time distribution from longitudinal biomarker trajectories using iterative regression and continuous time Markov processes by Alice Cleynen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2503-10448.txt.

Introduction

Blood markers can track a cancer's course, but the day a patient relapses is rarely seen directly, since many leave the study first. Cleynen and co-authors build a method that reads the marker's path over time and estimates when the hidden status change happened. They frame the problem with a class of random processes that drift smoothly and jump at random moments, the marker playing the role of a stand-in for the patient's state.

An iterative regression procedure fits the change dates in continuous time, which yields the full distribution of relapse times for the group. Simulations test the method against rivals, and myeloma patient data illustrate it. The authors call the work a proof of concept.

Catalog record

CREATORAlice Cleynen
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2503-10448

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Estimating relapse time distribution from longitudinal biomarker trajectories using iterative regression and continuous time Markov processes Alice Cleynen Abstract Abstract. Biomarker measurements obtained by blood sampling are often used as a non-invasive means of monitoring tumour progression in cancer patients. Diseases evolve dynamically over time, and studying longitudinal observations of specific biomarkers can help to understand patients response to treatment and predict disease progression. We propose a novel iterative regression-based method to estimate changes in patients status within a cohort that includes censored patients, and illustrate it on clinical data from myeloma cases. We formulate the relapse time estimation problem in the framework of Piecewise Deterministic Markov processes (PDMP), where the Euclidean component is a surrogate biomarker for patient state. This approach enables continuous-time estimation of the status-change dates, which in turn allows for accurate inference of the relapse time distribution. A key challenge lies in the partial observability of the process, a complexity that has been rarely addressed in previous studies. . We evaluate the performance of our procedure through a simulation study and compare it with different approaches. This work is a proof of concept on biomarker trajectories with simple behaviour, but our method can easily be extended to more complex dynamics. Keywords. Piecewise Deterministic Markov Processes, Relapse time, Partial observations, Regression, Censoring 1 Introduction Biomarker measurements obtained by blood sampling are often used as a non-invasive means of monitoring tumour progression in cancer patients. Diseases evolve dynamically over time, and the study of longitudinal observations of specific biomarkers can help to understand patient response to treatment and predict disease progression. However, to date, most event dates (remission, relapse) are assigned on visit dates and are based on biomarker values exceeding common thresholds or deviating from reference levels, depending on the experience and personal knowledge of each practitioner. It is therefore of interest to develop statistical methods that would automate and refine the assignment of event dates to allow better understanding of the disease progression and improved prognosis of the patients, so that practitioner may adapt decisions. This is a challenging task, as diseases evolve continuously and dynamically over time, whereas biomarker values are only available at discrete times and measured in noise. Our study focuses on a cohort of patients followed after developing myeloma as part of a study conducted by the Inter-Groupe Francophone du Myélome in 2009 ( Attal et al. 2017 ) . We aim to estimate their date of entry into remission and date of relapse if any, based on their biomarker levels. The time between these two dates represents the relapse time, the behaviour of which is crucial for understanding disease progression. One of the difficulties of the problem lies in the fact that our observations are noisy and only give partial information: we have a measurement of a biomarker at discrete visit dates, but its true value at and between dates is unknown. Longitudinal biomarker observations have been studied in various ways to model disease progression. This includes the early detection of a certain event ( Amoros et al. 2019 ; Drescher et al. 2013 ; Han et al. 2020 ; Tang et al. 2017 ) , or the estimation of a disease phases by detecting discrete changes in disease states ( Severson et al. 2020 ; Lorenzi et al. 2019 ; Bartolomeo et al. 2011 ) , or estimating a consistent ordering of disease events ( Fonteijn et al. 2012 ) . In ( van Delft et al. 2022 ) , the authors compare 9 strategies for the analysis of longitudinal biomarker data. In most studies that focus on the occurrence of an event of interest, the date of the event is studied alone, in relation to an initial date, often corresponding to the start of follow-up. In our approach, we divide this duration into two phases, namely time to remission relative to the starting point, and time to relapse relative to entry into remission. We propose to embed this duration estimation problem in the framework of Piecewise Deterministic Markov Processes (PDMPs) ( Davis 1984 ) . These are continuous-time processes that can handle both continuous and discrete variables. They are used to describe deterministic motions punctuated by random jumps, and are therefore particularly well suited to our problem. Here we will consider a simple PDMP, and will aim at estimating its hazard rate (jump intensity). Statistical estimation for the hazard rate of PDMPs has been studied in the literature, but remains a challenging task in practice. Azaïs and Bouguet 2018 gives a general overview of recent methods for statistical parameter estimation in PDMPs based on a wide range of application examples, in both parametric and non-parametric frameworks. Examples of non parametric methods to estimate the jump mechanism under different settings and assumptions can be found in, Krell 2016 , Azaïs et al. 2014 or Krell and Schmisser 2021 for instance. In all papers, a single trajectory of the process is fully observed in long time. To the best of our knowledge, there exists no method to estimate the hazard rate of a PDMP with hidden jump times. We will present a new approach to estimate remission and relapse times of individuals, as well as the distribution of relapse time in a cohort of patients. It is based on two-sided iterative regression and survival analysis. The remainder of the paper is organized as follows. Section 2 introduces the data of interest and the statistical problem. In Section 3 , we define PDMPs and present our proposed framework for relapse time estimation. We conduct a simulation study to evaluate the performance of our method in Section 4 , where we also compare with different existing approaches. The results obtained from applying our estimation method to the real data are presented in Section 5 . We conclude with a discussion. 2 Data description and problem We are interested in patients undergoing medical follow-up after developing myeloma. Our data come from a study carried out by the Inter-Groupe Francophone du Myélome in 2009 ( Attal et al. 2017 ) . A cohort of 763 patients with newly diagnosed myeloma was followed-up after receiving therapy. Their M-protein levels were measured at different time intervals as a proxy for the progression of their disease — the higher the level of the biomarker the more severe the condition. At the start of their monitoring, patients have a pathological biomarker level and are administered a treatment, the effect of which is to reduce the M-protein level. If the level falls below a certain fixed threshold, the patient is considered to be in remission. In the event of a relapse, the serum level rises again. Patients may remain in remission, suffer a relapse or leave the study for various reasons. The length of follow-up therefore varies from one individual to another. Biomarker levels are measured during follow-up visits, the frequency of which can vary widely depending on the patient’s condition. Some examples of trajectories taken from the dataset are shown in Figure 1 . Low biomarker levels can be arbitrarily set to zero by practitioners, if considered negligible. Figure 1 : Some examples of trajectories from the dataset. The crosses correspond to observations and the black lines in between

Read the complete text